Open AccessNivolumab‐induced severe acute kidney injury with a long latent phase in a patient with non‐small‐cell lung cancer: A case report
Author(s) -
Uchida Naohiro,
Tsuji Seijiro,
Fujita Kohei,
Koizumi Mitsuteru,
Moriyoshi Koki,
Mio Tadashi
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1848
Subject(s) - nivolumab , medicine , acute kidney injury , kidney cancer , adverse effect , lung cancer , immunotherapy , renal cell carcinoma , immune system , cancer , oncology , immunology
Key Clinical Message In the treatment of immunotherapy with immune checkpoint inhibitors, we often experience immune‐related adverse event which manifest most frequently as a skin disorder, and very rarely as a renal disorder. In our manuscript, we report the case of a 71‐year‐old man with nivolumab‐induced severe acute kidney injury (AKI) in which the time from treatment initiation to the onset of AKI was the longest among the previously reported cases (377 days). Prolonged follow‐up is therefore warranted to detect late‐onset AKI.